company background image
PAB

Patrys ASX:PAB Stock Report

Last Price

AU$0.02

Market Cap

AU$41.1m

7D

-13.0%

1Y

-51.2%

Updated

01 Oct, 2022

Data

Company Financials
PAB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PAB Stock Overview

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.

Patrys Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Patrys
Historical stock prices
Current Share PriceAU$0.02
52 Week HighAU$0.046
52 Week LowAU$0.019
Beta0.069
1 Month Change-25.93%
3 Month Change-4.76%
1 Year Change-51.22%
3 Year Change-4.76%
5 Year Change33.34%
Change since IPO-96.85%

Recent News & Updates

Sep 01
Will Patrys (ASX:PAB) Spend Its Cash Wisely?

Will Patrys (ASX:PAB) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

PABAU BiotechsAU Market
7D-13.0%2.1%-1.7%
1Y-51.2%-5.6%-10.8%

Return vs Industry: PAB underperformed the Australian Biotechs industry which returned -5.6% over the past year.

Return vs Market: PAB underperformed the Australian Market which returned -10.8% over the past year.

Price Volatility

Is PAB's price volatile compared to industry and market?
PAB volatility
PAB Average Weekly Movement9.3%
Biotechs Industry Average Movement10.2%
Market Average Movement9.4%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market4.2%

Stable Share Price: PAB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PAB's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aJames Campbellhttps://www.patrys.com

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer.

Patrys Fundamentals Summary

How do Patrys's earnings and revenue compare to its market cap?
PAB fundamental statistics
Market CapAU$41.14m
Earnings (TTM)-AU$6.78m
Revenue (TTM)AU$3.33m

12.3x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PAB income statement (TTM)
RevenueAU$3.33m
Cost of RevenueAU$0
Gross ProfitAU$3.33m
Other ExpensesAU$10.11m
Earnings-AU$6.78m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0033
Gross Margin100.00%
Net Profit Margin-203.40%
Debt/Equity Ratio0.0%

How did PAB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PAB?

Other financial metrics that can be useful for relative valuation.

PAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.4x
Enterprise Value/EBITDA-4.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PAB's PS Ratio compare to its peers?

PAB PS Ratio vs Peers
The above table shows the PS ratio for PAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average10x
DXB Dimerix
7.9xn/aAU$51.3m
BIT Biotron
21.2xn/aAU$33.0m
EX1 Exopharm
5xn/aAU$21.2m
CYP Cynata Therapeutics
5.8xn/aAU$45.1m
PAB Patrys
12.3xn/aAU$41.1m

Price-To-Sales vs Peers: PAB is expensive based on its Price-To-Sales Ratio (12.3x) compared to the peer average (10x).


Price to Earnings Ratio vs Industry

How does PAB's PE Ratio compare vs other companies in the AU Biotechs Industry?

Price-To-Sales vs Industry: PAB is good value based on its Price-To-Sales Ratio (12.3x) compared to the Australian Biotechs industry average (19.7x)


Price to Sales Ratio vs Fair Ratio

What is PAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PAB's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of PAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PAB's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Patrys forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Patrys has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Patrys's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Patrys competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Patrys performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-37.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PAB is currently unprofitable.

Growing Profit Margin: PAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PAB is unprofitable, and losses have increased over the past 5 years at a rate of 37.9% per year.

Accelerating Growth: Unable to compare PAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).


Return on Equity

High ROE: PAB has a negative Return on Equity (-50.5%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Patrys's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PAB's short term assets (A$13.5M) exceed its short term liabilities (A$542.8K).

Long Term Liabilities: PAB has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PAB is debt free.

Reducing Debt: PAB has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PAB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PAB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.6% each year


Discover healthy companies

Dividend

What is Patrys's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Patrys Dividend Yield vs Market
How does Patrys dividend yield compare to the market?
SegmentDividend Yield
Company (Patrys)n/a
Market Bottom 25% (AU)2.8%
Market Top 25% (AU)7.2%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Patrys)n/a

Notable Dividend: Unable to evaluate PAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PAB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PAB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

James Campbell

7.83yrs

Tenure

AU$718,035

Compensation

Dr. James A. Campbell, BSc(Hons), PhD, MBA, GAICD, serves as Chief Executive Officer and Managing Director for Patrys Limited since April 13, 2015. Dr. Campbell serves as Principal of Gemini Biotechnology....


CEO Compensation Analysis

James Campbell's Compensation vs Patrys Earnings
How has James Campbell's remuneration changed compared to Patrys's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022AU$718kAU$327k

-AU$7m

Mar 31 2022n/an/a

-AU$7m

Dec 31 2021n/an/a

-AU$7m

Sep 30 2021n/an/a

-AU$5m

Jun 30 2021AU$601kAU$325k

-AU$4m

Mar 31 2021n/an/a

-AU$4m

Dec 31 2020n/an/a

-AU$3m

Sep 30 2020n/an/a

-AU$3m

Jun 30 2020AU$434kAU$318k

-AU$3m

Mar 31 2020n/an/a

-AU$3m

Dec 31 2019n/an/a

-AU$3m

Sep 30 2019n/an/a

-AU$2m

Jun 30 2019AU$504kAU$305k

-AU$411k

Mar 31 2019n/an/a

-AU$511k

Dec 31 2018n/an/a

-AU$611k

Sep 30 2018n/an/a

-AU$2m

Jun 30 2018AU$399kAU$280k

-AU$2m

Mar 31 2018n/an/a

-AU$2m

Dec 31 2017n/an/a

-AU$2m

Sep 30 2017n/an/a

-AU$1m

Jun 30 2017AU$338kAU$280k

-AU$1m

Mar 31 2017n/an/a

-AU$1m

Dec 31 2016n/an/a

-AU$1m

Sep 30 2016n/an/a

-AU$1m

Jun 30 2016AU$220kAU$218k

-AU$1m

Compensation vs Market: James's total compensation ($USD462.59K) is above average for companies of similar size in the Australian market ($USD274.64K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PAB's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: PAB's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

ASX:PAB Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Apr 22SellAU$776,353Mason Stevens LimitedCompany22,426,656AU$0.035
30 Mar 22BuyAU$92,487Mason Stevens LimitedCompany2,245,650AU$0.041
06 Dec 21SellAU$81,569Macquarie Investment Management LimitedCompany2,039,214AU$0.04
23 Nov 21BuyAU$5,064Macquarie Investment Management LimitedCompany129,661AU$0.039
08 Nov 21BuyAU$2,465,011Macquarie Investment Management LimitedCompany70,428,571AU$0.035
05 Nov 21SellAU$0Macquarie Investment Management LimitedCompany1,581,169AU$0.05

Ownership Breakdown

What is the ownership structure of PAB?
Owner TypeNumber of SharesOwnership Percentage
Private Companies274,085,38913.3%
Institutions303,396,48514.7%
Individual Insiders340,061,90116.5%
General Public1,139,455,98255.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.


Top Shareholders

Top 25 shareholders own 44.61% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.18%
Mason Stevens Limited
188,815,565A$3.8m18.95%12.22%
6.22%
Dax Calder
128,000,000A$2.6m6.56%no data
4.8%
Michael Stork
98,773,814A$2.0m0%no data
4.79%
Macquarie Investment Management Limited
98,464,596A$2.0m0%0.05%
3.16%
Dax Calder Pty Ltd
65,000,000A$1.3m8.33%no data
2.65%
The Konda Family Trust
54,549,882A$1.1m15.27%no data
1.94%
Kemast Investments Pty Ltd
39,814,272A$796.3k8.33%no data
1.73%
Estelleanne Pty Ltd
35,500,000A$710.0k73.17%no data
1.65%
Mladen Marusic
34,000,000A$680.0k13.33%no data
1.51%
Marginata Pty Ltd
31,000,000A$620.0k0%no data
1.31%
Staffwear Pty Ltd
27,000,000A$540.0k0%no data
0.92%
James Campbell
18,885,125A$377.7k0%no data
0.78%
Yale University Investments
16,116,324A$322.3k0%0.14%
0.65%
Justin Puddick
13,300,000A$266.0k0%no data
0.56%
Karin Jones
11,595,961A$231.9k0%no data
0.55%
Valui Pty Ltd
11,250,012A$225.0k-8.16%no data
0.53%
Peter Bradfield
11,000,000A$220.0k0%no data
0.5%
Xie Xiaoke
10,250,000A$205.0k2.5%no data
0.48%
Edstop Pty Ltd
9,971,223A$199.4k9.39%no data
0.43%
John Read
8,785,849A$175.7k0%no data
0.15%
Susan Jones
3,000,000A$60.0k0%no data
0.05%
Harrison Read
1,031,545A$20.6k0%no data
0.05%
Suzannah Read
1,031,522A$20.6k0%no data
0.012%
Pamela M. Klein
250,000A$5.0k0%no data
0.0077%
Linda Greenhow
158,085A$3.2k0%no data

Company Information

Patrys Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Patrys Limited
  • Ticker: PAB
  • Exchange: ASX
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$41.140m
  • Shares outstanding: 2.06b
  • Website: https://www.patrys.com

Location

  • Patrys Limited
  • 100 Albert Road
  • Level 4
  • Melbourne
  • Victoria
  • 3205
  • Australia


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PABASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJul 2007
PATL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2007
PABCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJul 2007

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2022/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.